Wuhan Institute Develops Broad‑Spectrum Ebola Vaccine
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Yanfeng Yao and his team at the Wuhan Institute of Virology designed a broad‑spectrum mRNA vaccine that encodes the glycoproteins of Zaire, Sudan and Bundibugyo Ebola viruses plus their shared nucleoprotein, packaged in a lipid nanoparticle.
- The vaccine gave complete protection to mice against Zaire and Sudan viruses and strong protection against Bundibugyo, and also protected hamsters from Sudan virus.
- Bundibugyo virus has infected over 600 people in the DRC and two confirmed cases in Uganda, prompting the World Health Organization to declare a public health emergency of international concern.
- World Health Organization declared the Bundibugyo outbreak a public health emergency of international concern.
- Robert Cross of the University of Texas Medical Branch warned that testing in non‑human primates is the gold standard for predicting human efficacy.
Why it matters: The vaccine’s broad‑spectrum design has the potential to efficiently mitigate outbreaks caused by multiple orthoebolaviruses, a crucial advantage as the Bundibugyo strain has already infected >600 people and triggered a WHO emergency.
